Achieve Life Sciences Secures $354M Financing, Preps for Cytisinicline Launch
Event summary
- Closed $354M private placement, including $180M upfront and $174M in milestone-driven warrants.
- Appointed Andrew D. Goldberg, MD as CEO and expanded board with three new directors.
- Partnered with Adare Pharma Solutions for U.S.-based commercial manufacturing.
- Expects Complete Response Letter from FDA by June 20, 2026, with NDA resubmission in Q4 2026.
- Published positive clinical data in Nicotine & Tobacco Research and presented at SRNT 2026.
The big picture
Achieve Life Sciences is positioning itself for a potential 2027 launch of cytisinicline, the first new FDA-approved smoking cessation therapy in over two decades. The $354M financing and leadership changes signal a strategic shift toward commercialization, while the manufacturing partnership with Adare Pharma Solutions ensures U.S.-based production capacity. The company's focus on both smoking and vaping cessation addresses a critical public health need, with the FDA's Breakthrough Therapy designation highlighting the unmet demand for effective treatments.
What we're watching
- Regulatory Timing
- Whether the FDA's Complete Response Letter by June 20, 2026, will clear the path for a smooth NDA resubmission in Q4 2026.
- Commercial Readiness
- The pace at which Achieve can finalize its commercial leadership and manufacturing transition ahead of a potential 2027 launch.
- Clinical Differentiation
- How the positive Phase 3 data and post-trial survey results will position cytisinicline against existing smoking cessation therapies.
Related topics